Drug intelligence / Profile preview

SRNA-005

Development stage: Unknown
Lead developer: Serna Bio
Modality: Small Molecules

Overview

SRNA-005 is a preclinical-stage, RNA-targeted small molecule drug candidate being developed by Serna Bio. It is designed to modulate the Hippo/YAP-TAZ signaling pathway, which plays a critical role in cell proliferation, tissue regeneration, and tumorigenesis. Serna Bio utilizes its proprietary AI-native discovery platform, which combines machine learning with large-scale datasets of RNA-small molecule interactions, to design small molecules that target functional RNA structures and precisely regulate protein expression. SRNA-005 is currently available for partnership.

Beyond the preview

Go deeper on SRNA-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRNA-005.

Explore the full profile